DFCM
CRSP icon

Dark Forest Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Dark Forest Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.38M Buy
25,350
+6,594
+35% +$348K 0.09% 400
2026
Q1 		$892K Sell
18,756
-1,183
-6% -$62.4K 0.08% 403
2025
Q4 		$1.05M Buy
+19,939
New +$1.19M 0.05% 632
2022
Q1 		– Sell
-160
Closed -$12K – 1362
2021
Q4 		$12K Buy
+160
New +$14K ﹤0.01% 857
2021
Q3 		– Sell
-217
Closed -$35K – 1310
2021
Q2 		$35K Buy
+217
New +$26.4K 0.02% 493

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Dark Forest Capital Management's CRSP Position: Q2 2026 in Review

Dark Forest Capital Management increased its CRISPR Therapeutics (CRSP) stake by 35% in Q2 2026, buying an estimated $348K and bringing the position to 25,350 shares worth $1.38M. The position accounts for 0.09% of the portfolio, ranked #400.

Dark Forest Capital Management first reported a position in CRSP in Q2 2021 and has held it in 5 quarters since. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Dark Forest Capital Management held 25,350 shares of CRISPR Therapeutics worth $1.38M as of Q2 2026.
  • Dark Forest Capital Management bought 6,594 CRISPR Therapeutics shares in Q2 2026, an estimated $348K.
  • CRISPR Therapeutics made up 0.09% of Dark Forest Capital Management's portfolio in Q2 2026, its #400 holding.
  • Dark Forest Capital Management first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 5 quarters since.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Dark Forest Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.